Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A community-based study of antibiotic consumption in an urban health training centre area of Ahmedabad city.

The Indian journal of medical research·2026

Same author

Challenges and developments in the manufacturing of high-concentration biotherapeutic monoclonal antibodies.

Advanced drug delivery reviews·2026

Same author

Sustainable Synthesis and Medicinal Profiling of Azo-Anchored Imidazo[4,5-b]Indole Scaffolds: DFT Studies, Electrochemical Sensing, and Pharmacokinetic Evaluation.

Archiv der Pharmazie·2026

Same author

Elucidating the potential of novel class biphenyl-phenyl acetate, IDD-AN-A1, an inhibitor targeting Isocitrate Lyase in Mycobacterium tuberculosis: A target to lead approach.

Bioorganic chemistry·2026

Same author

Green and Sustainable Approaches for the Synthesis of Imidazo[1,2-a]Pyridines: Advances, Challenges, and Future Perspectives.

Chemical record (New York, N.Y.)·2026

Same author

A Prospective Study of the Epidemiological Profile of Dog Bite Cases and Determinants of Anti-Rabies Vaccination Compliance at a Rural Health Training Center from a Medical College in Gujarat.

Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Biological agents targeting beyond TNF-alpha.

Rashmi Sharma¹, Chaman Lal Sharma, Annil Mahajan

¹Department of Pharmacology and Therapeutics, Govt. Medical College, Jammu (J and K) -180 001, India. rashmichams@yahoo.com

Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine

|September 11, 2009

Summary

This summary is machine-generated.

Biological agents offer new hope for immuno-inflammatory conditions. Newer therapies beyond anti-TNF agents show promise for improving patient quality of life.

Keywords:

Biological agents CD20 antigen T-cells cytokines rheumatology

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Related Experiment Videos

Last Updated: Jun 20, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Area of Science:

Immunology
Pharmacology
Biotherapy

Background:

Biological agents significantly impact immuno-inflammatory conditions.
Concerns regarding serious infections with anti-TNF therapy necessitate alternative treatments.
Focus is shifting to novel targets beyond TNF-alpha in inflammatory pathways.

Purpose of the Study:

To review emerging biological agents targeting cytokine checkpoints.
To explore novel immunomodulatory therapies for various diseases.
To highlight the potential of new treatments in improving patient outcomes.

Main Methods:

Review of existing literature on biological agents.
Analysis of therapeutic targets beyond TNF-alpha.
Discussion of novel molecules and their mechanisms of action.

Main Results:

Several biological agents target inflammatory cytokines (e.g., Anakinra, Tocilizumab) and co-stimulatory signals (e.g., Abatacept).
Other agents modulate T-cells (Alefacept), leukocyte function (Efalizumab), or B-cells (Rituximab).
These novel therapies offer promising avenues for managing rheumatology, asthma, Crohn's disease, and septic shock.

Conclusions:

Novel biological agents represent a promising future for immunomodulatory interventions.
These therapies offer new hope for clinicians to modify disease course.
Significant improvements in patient quality of life are anticipated with these advanced treatments.